Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06059261 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 45 to 30v3 Show 6 more changesShow less
    • Start date: Aug 4, 2024 to Feb 9, 2026
    • Primary endpoint revised
    • Primary and study completion dates: Oct 1, 2027 to Feb 1, 2027
    • Secondary endpoints revised (6)
    • Study description revised
    • Collaborators shortened, about 6 words
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Enrollment target: 30 to 45
    • Start date: Oct 1, 2023 to Aug 4, 2024
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 22 words
    • Study description expanded, about 8 words
    • Collaborators expanded, about 6 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.
Trial Details
NCT Number NCT06059261
Lead Sponsor Chongqing University Cancer Hospital
Conditions
(from sponsor)		 Nasopharyngeal Carcinoma
Related terms Nasopharyngeal Carcinoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov